ViroXis Corporation, a San Antonio, Texas-based life sciences company, has received a $2.5m investment from the Texas Emerging Technology Fund (TETF).
The award will allow ViroXis to advance the product development and commercialization of its topical Albuterpenoid drug, a patented anti-viral therapeutic derived from East Indian Sandalwood oil (EISO), aimed at treating common skin warts, a highly prevalent disease that currently lacks a successful means of treatment.
EISO has completed an investigational Phase IIb FDA approved clinical study with clinical investigators at the Children’s Hospital in Columbus, Ohio.
The therapeutic is for treatment of Human Papillomavirus (HPV), the cause of skin warts.
Commenting on the funding, Ian Clements, President and CEO of the company, said: “This significant investment in ViroXis by the Texas ETF will enable us to move our lead product into clinical trials, bringing us one step closer to launching a novel botanical drug for treatment of a serious and problematic skin condition”.